Daratumumab plus Lenalidomide/ dexamethasone in transplant-neligible patients with newly diagnosed multiple myeloma: MAIA update

被引：0

作者：

Basu, Supratik ^{[1
]}

Kumar, Shaji K. ^{[2
]}

Moreau, Philippe ^{[3
]}

Bahlis, Nizar ^{[4
]}

Facon, Thierry ^{[5
]}

Plesner, Torben ^{[6
,7
]}

Orlowski, Robert Z. ^{[8
]}

Nahi, Hareth ^{[9
]}

Hulin, Cyrille ^{[10
]}

Quach, Hang ^{[11
]}

Goldschmidt, Hartmut ^{[12
]}

O'Dwyer, Michael ^{[13
]}

Perrot, Aurore ^{[14
]}

Venner, Christopher P. ^{[15
]}

Weisel, Katja ^{[16
]}

Raje, Noopur ^{[17
]}

Tiab, Mourad ^{[18
]}

Macro, Margaret ^{[19
]}

Frenzel, Laurent ^{[20
]}

Leleu, Xavier ^{[21
]}

Pei, Huiling ^{[22
]}

Krevvata, Maria ^{[23
]}

Borgsten, Fredrik ^{[24
]}

Usmani, Saad Z. ^{[25
]}

机构：

[1] Royal Hosp Wolverhampton, Wolverhampton, England

[2] Mayo Clin Rochester, Dept Haematol, Rochester, MN USA

[3] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[4] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada

[5] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[6] Vejle Hosp, Vejle, Denmark

[7] Univ Southern Denmark, Vejle, Denmark

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[9] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Haematol, Dept Med, Stockholm, Sweden

[10] Univ Hosp Pessac, Dept Haematol, Hop Haut Leveque, Pessac, France

[11] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[12] Univ Heidelberg Hosp, GMMG Study Grp, Internal Med 5, Heidelberg, Germany

[13] NUI, Dept Med Haematol, Galway, Ireland

[14] UPS, Univ Toulouse, CHU Toulouse, IUCT O,Serv Hematol, Toulouse, France

[15] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[16] Univ Med Ctr Hamburg Eppendorf, Haematol & Bone Marrow Transplantat Sect Pneumol, Dept Oncol, Hamburg, Germany

[17] Massachusetts Gen Hosp, Ctr Multiple Myeloma, Canc Ctr, Boston, MA USA

[18] CHD Vendee, La Roche Sur Yon, France

[19] Ctr Hosp Univ CHU Caen, Caen, France

[20] Hop Necker Enfants Malad, Paris, France

[21] Hop Miletrie, CHU Poitiers, Poitiers, France

[22] Janssen Res & Dev LLC, Titusville, NJ USA

[23] Janssen Res & Dev LLC, Spring House, PA USA

[24] Janssen Res & Dev LLC, Raritan, NJ USA

[25] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-OR21

引用

页码：17 / 18

页数：2

共 50 条

[31] A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson Jr, Larry D.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
FUTURE ONCOLOGY, 2022, 18 (40) : 4443 - 4456
[32] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
Tan, Carlyn Rose
Maclachlan, Kylee
Nemirovsky, David
Derkach, Andriy
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi
Patel, Dhwani
Shekarkhand, Tala
Rueda, Colin
Lahoud, Oscar
Shah, Gunjan
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio
Usmani, Saad
Lesokhin, Alexander
Korde, Neha
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
[33] Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Perrot, Aurore
Facon, Thierry
Plesner, Torben
Usmani, Saad
Kumar, Shaji K.
Bahlis, Nizar Jacques
Hulin, Cyrille
Orlowski, Robert Z.
Nahi, Hareth
Mollee, Peter
Ramasamy, Karthik
Roussel, Murielle
Jaccard, Arnaud
Delforge, Michel
Karlin, Lionel
Arnulf, Bertrand
Chari, Ajai
Pei, Huiling
Gupta, Niodita
Kaila, Shuchita
Matt, Kathryn
Gries, Katharine S.
Carson, Robin
Borgsten, Fredrik
Weisel, Katja
BLOOD, 2022, 140 : 1142 - 1145
[34] Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Usmani, Saad Z.
Facon, Thierry
Hungria, Vania
Bahlis, Nizar J.
Venner, Christopher P.
Braunstein, Marc
Pour, Ludek
Marti, Josep
Basu, Supratik
Cohen, Yael C.
Matsumoto, Morio
Suzuki, Kenshi
Hulin, Cyrille
Grosicki, Sebastian
Legiec, Wojciech
Beksac, Meral
Maiolino, Angelo
Liu, Weiping
Wang, Jianping
Krevvata, Maria
Lopez-Masi, Lorena
Carey, Jodi
Rowe, Melissa
Carson, Robin
Zweegman, Sonja
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S288 - S289
[35] Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma
Kawano, Yawara
Hata, Hiroyuki
Takashio, Seiji
Tsujita, Kenichi
Ueda, Mitsuharu
Matsuoka, Masao
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : E38 - E41
[36] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
Leleu, Xavier
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Perrot, Aurore
Manier, Salomon
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Chretien, Marie Lorraine
Laribi, Karim
Dingremont, Claire
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Macro, Margaret
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
[37] Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Orlowski, Robert
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Ahmadi, Tahamtan
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S424 - S425
[38] Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves Over Time in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Griffin Study Update
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
De Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 127 - 128
[39] Lenalidomide plus dexamethasone effective in newly diagnosed myeloma
Kate Matthews
Nature Clinical Practice Oncology, 2006, 3 (3): : 116 - 117
[40] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Crusoe, Edvan de Queiroz
Ribeiro, Glaciano
Moura, Fernanda
Costa, Abel
Aranha, Milton
Bittencourt, Rosane
Ribeiro, Eduardo
Neto, Jorge
Cunha, Rafael
Mattos, Ederson
Braga, Walter
Lima, Juliana Souza
Gusmao, Breno
Lopes, Danielle Ovigli
Berg, Luiza
Souto, Joao
Maiolino, Angelo
Hungria, Vania T. M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223

← 1 2 3 4 5 →